Intercept Pharmaceuticals Inc. shares rallied in the extended session Thursday after a Food and Drug Administration advisory committee receommended an accelerated approval of the biotech’s liver treatment Ocaliva. Intercept shares surged 9% to $178.40 after hours. Intercept said the FDA’s Gastrointestinal Drugs Advisory Committee voted 17-0 to approve Ocaliva to treat primary biliary cholangitis, a liver disease that destroys bile ducts and causes cirrhosis. The FDA is not required to follow advisory committee recommendations but does for the most part.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.